{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:09:35Z","timestamp":1789657775523,"version":"4.0.1"},"reference-count":33,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,5,27]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.2967\/jnumed.126.272531","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:20:20Z","timestamp":1782397220000},"page":"1434-1439","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Restaging [\n                    <sup>18<\/sup>\n                    F]FDG PET\/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA-617 Therapy"],"prefix":"10.2967","volume":"67","author":[{"given":"Raghava","family":"Kashyap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Buteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narjess","family":"Ayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Eifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Betech-Antar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Akhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Alipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Saghebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind S.","family":"Ravi Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Cardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"2026091707501239000_67.9.1434.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026091707501239000_67.9.1434.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026091707501239000_67.9.1434.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"2026091707501239000_67.9.1434.4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026091707501239000_67.9.1434.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00440-6"},{"key":"2026091707501239000_67.9.1434.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.09.014"},{"key":"2026091707501239000_67.9.1434.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"},{"key":"2026091707501239000_67.9.1434.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267234"},{"key":"2026091707501239000_67.9.1434.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00605-2"},{"key":"2026091707501239000_67.9.1434.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264398"},{"key":"2026091707501239000_67.9.1434.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"2026091707501239000_67.9.1434.12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/MNM.0000000000001376","article-title":"Correlation between semiquantitative and volumetric 18F-FDG PET\/computed tomography parameters and Ki-67 expression in breast cancer","volume":"42","author":"Mohamadien","year":"2021","journal-title":"Nucl Med Commun."},{"key":"2026091707501239000_67.9.1434.13","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31818307a7"},{"key":"2026091707501239000_67.9.1434.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"},{"key":"2026091707501239000_67.9.1434.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263072"},{"key":"2026091707501239000_67.9.1434.16","first-page":"5000","article-title":"The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC)","volume":"33","author":"Scher","year":"2015","journal-title":"J Clin Orthod."},{"key":"2026091707501239000_67.9.1434.17","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707501239000_67.9.1434.18","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460"},{"key":"2026091707501239000_67.9.1434.19","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.7150\/thno.60222","article-title":"Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy","volume":"11","author":"Seifert","year":"2021","journal-title":"Theranostics."},{"key":"2026091707501239000_67.9.1434.20","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s00259-021-05594-8","article-title":"Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy","volume":"49","author":"Rosar","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707501239000_67.9.1434.21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00259-023-06476-x","article-title":"Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry","volume":"51","author":"Burgard","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707501239000_67.9.1434.22","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00259-023-06326-w","article-title":"Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"50","author":"Cytawa","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707501239000_67.9.1434.23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.euo.2025.02.012","article-title":"Immunohistochemical prostate-specific membrane antigen (PSMA) expression patterns of primary prostate cancer tissue as a determining factor for prostate cancer staging with PSMA positron emission tomography\/computed tomography","volume":"9","author":"Ambrosini","year":"2026","journal-title":"Eur Urol Oncol."},{"key":"2026091707501239000_67.9.1434.24","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0226"},{"key":"2026091707501239000_67.9.1434.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.262250"},{"key":"2026091707501239000_67.9.1434.26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13550-020-00640-2","article-title":"Neuron-specific enolase has potential value as a biomarker for [18F]FDG\/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients","volume":"10","author":"Rosar","year":"2020","journal-title":"EJNMMI Res."},{"key":"2026091707501239000_67.9.1434.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264104"},{"key":"2026091707501239000_67.9.1434.28","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.3390\/cancers13164134","article-title":"Value of combined PET imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC patients with worsening disease during [177Lu]Lu-PSMA-617 RLT","volume":"13","author":"Khreish","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026091707501239000_67.9.1434.29","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2023-177938","article-title":"Metabolic tumor volume from baseline PET\/CT improves stratification in the high IPI risk patients with diffuse large B-cell lymphoma","volume":"142","author":"Hanzhen","year":"2023","journal-title":"Blood."},{"key":"2026091707501239000_67.9.1434.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2822-7"},{"key":"2026091707501239000_67.9.1434.31","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1159\/000504673","article-title":"High metabolic tumour volume on 18-fluorodeoxyglucose positron emission tomography predicts poor survival from neuroendocrine neoplasms","volume":"110","author":"Chan","year":"2020","journal-title":"Neuroendocrinology."},{"key":"2026091707501239000_67.9.1434.32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12880-024-01525-9","article-title":"Clinico-pathological factors and [18F]FDG PET\/CT metabolic parameters for prediction of progression-free survival in radioiodine refractory differentiated thyroid carcinoma","volume":"24","author":"Phuong","year":"2024","journal-title":"BMC Med Imaging."},{"key":"2026091707501239000_67.9.1434.33","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:51:07Z","timestamp":1789656667000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,2]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.2967\/jnumed.126.272531"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272531","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]}}}